Arrowhead Completes Enrollment in Phase 1 Study of ARC-520
for the Treatment of Chronic Hepatitis B
- Safety and tolerability support advancement of ARC-520 into Phase 2a
PASADENA, Calif. - October 8, 2013 - Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.